Enhanced response inhibition in patients with drug-resistant juvenile myoclonic epilepsy: Event-related potentials evidence of excitatory-inhibitory imbalance. [PDF]
Sarah L+5 more
europepmc +1 more source
Reliability of the Probability Effect on Event-related Potentials during Repeated Testing.
Sayaka Kinoshita+4 more
openalex +2 more sources
Effects of zolpidem and zopiclone on cognitive and attentional function in young healthy volunteers: An event‐related potential study [PDF]
Toru Nakajima+5 more
openalex +1 more source
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira+14 more
wiley +1 more source
Task-related changes in aperiodic activity are related to visual working memory capacity independent of event-related potentials and alpha oscillations. [PDF]
Virtue-Griffiths S+7 more
europepmc +1 more source
P01.127 Event related potentials (CNV and P300) in chronic opiate users: Preliminary results [PDF]
E. Pinto+5 more
openalex +1 more source
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian+10 more
wiley +1 more source
EEG Baseline Analysis for Effective Extraction of P300 Event-Related Potentials for Welfare Interfaces. [PDF]
Sasatake Y, Matsushita K.
europepmc +1 more source
Effects of risperidone on auditory event-related potentials in schizophrenia
Daniel Umbricht+6 more
openalex +2 more sources
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga+8 more
wiley +1 more source